Blazar
Blazar uses machine learning to predict cancer response to immunotherapy.
Immunotherapies are a groundbreaking cancer treatment curing patients with a success impossible five years ago. Unfortunately they work in only 20% of patients, may cause several adverse effects and are very costly to develop.
At Blazar we apply machine learning to patient data providing predictions and insights on treatment response. This allows for better patient recruitment for clinical trials and better understanding on failure reasons.
Leading clinical centers have already trusted their patient data with us and we are negotiating pilots with more than 20 partners around the world.
Founders
Dora Sabino
CEO, Blazar
Experience in cancer research, led projects in industry-modelling cancer treatment response
Renan Pereira
CTO, Blazar
Data scientist, experience developing and managing scalable machine learning models